• Mashup Score: 0

    Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE…

    Tweet Tweets with this article
    • 📢 Check out this insightful video from the STAMPEDE trial platform, featuring @marina_parry and @AttardLab! 🎥 sharing valuable insights into advanced #ProstateCancer research. Don't miss it! #MedicalResearch #CancerTreatment #STAMPEDEtrial > https://t.co/O8lFEdAhpP https://t.co/oSIddYLp9f

  • Mashup Score: 0

    Aims Adenomas of the ciliary body epithelium, including adenoma of the pigmented ciliary body epithelium (APCE) and adenoma of the non-pigmented ciliary body epithelium (ANPCE), are extremely rare, and most knowledge about them comes from sporadic case reports. The purpose of this study was to provide a comprehensive understanding of adenomas of the ciliary body epithelium and to identify the similarities and differences between APCE and ANPCE. Methods This study was a retrospective case series comprising data from 41 patients obtained from retrieved publications and five cases diagnosed at the Shanghai Ninth People’s Hospital. The clinicopathological features, treatment and prognosis of APCE and ANPCE were compared using the non-parametric rank sum test, t-test and the χ2 test. Results The clinical and histopathological features and treatment were analogous between APCE (n=23) and ANPCE (n=23). The overall visual prognosis associated with the two tumours was good, with 63% of the pati

    Tweet Tweets with this article
    • "Discover rare eye tumors! 🌟 Learn about ciliary body epithelium adenomas - APCE & ANPCE. Findings reveal insights on prognosis & treatment. A must-read for medical enthusiasts! 📚 #MedicalResearch" https://t.co/icBO9a8wui

  • Mashup Score: 0

    Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia that was presented at ASH in New Orleans. So I think there were so many great talks. There were so many great talks and I decided I would focus on just three and really…

    Tweet Tweets with this article
    • 🚀 #ASH22 Updates in ALL Immunotherapy with Inotuzumab! Van Huynh, MD @MOASC_Office @UCIrvineHealth, shared insights at #MOASC23. 🩺 Discover remarkable breakthroughs![Video]🎥: https://t.co/BBlUqPvBAS 💊 #oncology #leukemia #medicalresearch #Immunotherapy #UCIMedSchool #CARTcell https://t.co/OSKdxJCTLI